Thyroid Eye Disease (Graves’ Ophthalmopathy): Complete Guide
Understanding Thyroid Eye Disease
If you have noticed your eyes looking or feeling different since a thyroid diagnosis, you are not alone, and your concerns are valid. Thyroid eye disease (TED), also called Graves' ophthalmopathy or thyroid-associated orbitopathy, is an autoimmune condition that causes inflammation and swelling of the muscles, fat, and connective tissue within the eye socket. It is the most common cause of bulging eyes in adults and most frequently develops alongside Graves' disease, an autoimmune condition in which the thyroid gland is overstimulated. According to a large United States eye care database, TED affects approximately 0.09 percent of the overall population, with women affected three times more often than men (IRIS Registry, PMC, 2025).
TED occurs most frequently in patients with Graves' disease. Approximately 40 percent of people with Graves' disease worldwide develop some degree of eye involvement (PMC meta-analysis, 2023). However, TED can also develop in patients with Hashimoto's thyroiditis or even in individuals with normal thyroid function, though these cases are far less common. Regardless of which thyroid condition is present, the eye changes share the same underlying immune-driven process.
Certain factors increase the likelihood and severity of TED. Smoking is the single most significant modifiable risk factor and can make symptoms substantially worse. Other risk factors include:
- Uncontrolled thyroid hormone levels, whether too high or too low
- Treatment with radioactive iodine for hyperthyroidism, particularly without steroid protection
- Female sex, though men tend to develop more severe disease when affected
- Age, with peaks in incidence during the 40s to 60s and again in older adults
- Family history of autoimmune thyroid disease
How Graves' Disease Affects the Eyes
In Graves' disease, antibodies mistakenly target receptors on thyroid cells, stimulating excess hormone production. These same antibodies also bind to receptors on specialized cells called orbital fibroblasts (cells that reside in the tissue behind the eyes). Once activated, these fibroblasts produce large amounts of a sugar-protein substance called glycosaminoglycans that absorbs water and causes significant tissue swelling within the eye socket. The insulin-like growth factor 1 receptor (IGF-1R) on these fibroblasts plays a central role in amplifying this inflammatory response.
The inflammation triggered by this autoimmune process leads to enlargement of the muscles that move the eyes and expansion of the fat cushion behind the eyeball. Because the bony eye socket cannot stretch to accommodate this extra volume, the eyeball is pushed forward, creating the protruding appearance known as proptosis (bulging eyes). In some patients, the swollen muscles restrict eye movement and lead to diplopia (double vision), while increased pressure within the orbit can affect blood flow and nerve function.
One of the more confusing aspects of TED is that eye symptoms do not always track with thyroid hormone levels. Some patients develop eye changes months or even years before, during, or after thyroid problems are identified. Controlling thyroid hormone levels is important for overall health and can influence the course of TED, but normalizing thyroid function alone does not necessarily resolve the eye condition. This disconnect is why specialized monitoring by our oculoplastic surgeon is essential even when thyroid levels appear well managed.
Recognizing the Symptoms
Many patients first notice a dry, gritty sensation in their eyes, increased tearing, or a feeling of pressure behind the eyes. Puffiness or swelling around the eyelids is also common in the early stages. This swelling from TED is typically symmetrical and involves both upper and lower lids, which can help distinguish it from localized bumps such as a chalazion or stye. Some patients also develop excess upper eyelid skin or drooping that resembles dermatochalasis, though the cause is different. When these changes accompany a known thyroid condition, a thorough eye evaluation is appropriate.
As TED advances, more noticeable changes may develop. The eyes may begin to appear more prominent or bulging, and the upper eyelids may retract, giving a wide-eyed or staring appearance. Light sensitivity often increases, and some patients experience aching pain when looking up, down, or to the side. Double vision can develop as the enlarged eye muscles lose their ability to coordinate movement properly.
In a small percentage of patients, TED can threaten vision. Compressive optic neuropathy (pressure on the optic nerve from swollen tissues) occurs when enlarged muscles press on the nerve at the back of the eye socket, potentially causing blurred vision, faded color perception, or progressive vision loss. Severe proptosis can also prevent the eyelids from fully closing, leading to corneal exposure and possible ulceration. Any sudden decline in vision, new color vision changes, or an inability to close the eyelids fully warrants urgent evaluation. If you are also experiencing a droopy eyelid alongside other eye changes, our oculoplastic surgeon can help determine whether it is related to TED or another condition such as ptosis.
Stages and Progression of Thyroid Eye Disease
During the active phase, the immune system is actively inflaming the orbital tissues. You may experience worsening redness, swelling, pain, and progressive eye changes during this time. We use the Clinical Activity Score (CAS), a standardized tool that measures signs of active inflammation including spontaneous eye pain, pain with eye movement, eyelid redness, and tissue swelling. A CAS of 3 or higher out of 7 generally indicates active disease that may benefit from anti-inflammatory treatment. This is the window during which medical therapies can have the greatest impact on reducing long-term damage.
After the active inflammatory phase subsides, TED enters its inactive or stable phase. Inflammation resolves, but the structural changes it caused, such as proptosis, eyelid retraction, or restricted eye movement, may persist. Once the disease has been stable for at least six months, surgical rehabilitation can be considered to address these residual changes and restore both function and appearance.
The natural progression of TED is often illustrated by Rundle's curve, a model showing disease severity increasing during the active phase, reaching a peak, and then gradually declining into the inactive phase. The plateau that follows the decline represents the lasting structural changes. Early intervention during the active phase can reduce the peak severity and limit the degree of permanent change, which underscores why timely diagnosis and treatment planning are so valuable.
Treatment Options
When TED is actively inflamed, the primary goal of treatment is to reduce the immune-driven swelling before it causes permanent structural changes. Options include intravenous corticosteroids, which can suppress inflammation, and orbital radiation therapy in selected cases. Tepezza (teprotumumab) is the first FDA-approved medication specifically designed for TED. It works by blocking the IGF-1R on orbital fibroblasts, which interrupts the inflammatory process driving tissue swelling and proptosis. Given as a series of eight intravenous infusions over approximately 24 weeks, clinical trials have shown significant reductions in eye bulging, double vision, and overall disease activity.
Surgery is typically reserved for the inactive phase of TED or for emergencies such as compressive optic neuropathy. Surgical rehabilitation follows a specific sequence for the best results. Orbital decompression is performed first to reduce proptosis by removing portions of bone or fat from the eye socket. If double vision persists after decompression, strabismus surgery adjusts the eye muscles to restore proper alignment. Finally, eyelid surgery corrects any remaining retraction or cosmetic concerns. Our oculoplastic surgeon follows this staged approach to ensure that each procedure builds on the results of the one before it.
Throughout all stages of TED, several supportive measures can help manage daily discomfort. Preservative-free artificial tears and lubricating ointments help protect the corneal surface. Sleeping with the head elevated can reduce morning eyelid swelling. Wearing sunglasses with wraparound frames helps with light sensitivity and wind exposure. If you smoke, stopping is one of the most important steps you can take, as smoking worsens TED severity and reduces the effectiveness of treatment.
Living with Thyroid Eye Disease
We understand that TED affects far more than your eyes. Changes to facial appearance, persistent discomfort, and the unpredictability of the disease can take a real toll on confidence and emotional well-being. Many patients feel self-conscious about the visible changes or frustrated by how long the disease course can last. These feelings are entirely normal, and acknowledging them is an important part of your overall care. If you are struggling, we encourage you to discuss this with your care team so that appropriate support can be arranged.
TED is best managed by a team of specialists working together. Our oculoplastic surgeon provides the eye-specific care, including monitoring disease activity, coordinating medical treatments, and performing any necessary surgeries. An endocrinologist manages the underlying thyroid condition and helps optimize hormone levels. In some cases, additional specialists such as those who evaluate orbital tumors and growths may be consulted if imaging findings need further clarification. Coordination among these providers ensures the most comprehensive care for both your eyes and your overall health.
Even after TED enters its stable phase, ongoing follow-up is important. We monitor for any signs of reactivation, assess whether residual changes might benefit from surgical correction, and ensure that your tearing and eye surface health remain well managed. Regular visits also give us the opportunity to address any new concerns as they arise, keeping your care proactive rather than reactive.
Frequently Asked Questions
Diagnosis typically begins with a comprehensive eye examination, including measurement of eyelid position, degree of proptosis using an exophthalmometer (a specialized instrument that measures how far the eyes protrude), and assessment of eye movements and visual acuity. Imaging studies such as a CT scan or MRI of the orbits may be ordered to evaluate the size of the eye muscles and orbital fat and to check for optic nerve compression. Blood tests for thyroid function and thyroid antibodies help confirm the underlying autoimmune condition and guide overall management.
The active inflammatory phase of TED typically lasts between one and three years, though the duration varies considerably from person to person. Factors such as smoking, unstable thyroid hormone levels, and the timing of treatment all influence how long the active phase persists. Because effective treatment during this window can reduce the extent of long-term damage, consistent monitoring throughout the active phase is essential.
While most cases of TED do not result in permanent vision loss, the condition can threaten sight in several ways. Compressive optic neuropathy is the most serious complication and requires urgent treatment with high-dose corticosteroids or emergency orbital decompression. Severe corneal exposure from incomplete eyelid closure can also compromise vision if left unaddressed. With proper monitoring and timely intervention, serious vision loss from TED is uncommon.
The degree of improvement depends on several factors, including the severity of the disease, how early treatment was started, and which treatments were used. Many patients experience meaningful improvement in proptosis, double vision, and overall comfort, particularly with newer therapies such as Tepezza. However, some residual changes may remain after the active phase resolves, which is why staged surgical rehabilitation is available to address persistent proptosis, eye misalignment, or eyelid position concerns.
Most medical treatments for TED, including corticosteroids, Tepezza infusions, and surgical procedures, are considered medically necessary and are typically covered by insurance, though coverage specifics vary by plan. We recommend contacting your insurance provider before starting treatment to understand your benefits and any prior authorization requirements. Our team can assist with the documentation needed to support your coverage.
What our Patients say
4.8
Reviews
(3,408)